When choosing statin therapy: The case for generics

Jonas B. Green, Joseph S. Ross, Cynthia A. Jackevicius, Nilay D Shah, Harlan M. Krumholz

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The development of 'Top 5' lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

Original languageEnglish (US)
Pages (from-to)229-232
Number of pages4
JournalJAMA Internal Medicine
Volume173
Issue number3
DOIs
StatePublished - Jan 11 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risk Reduction Behavior
Therapeutics
Physicians
Costs and Cost Analysis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Green, J. B., Ross, J. S., Jackevicius, C. A., Shah, N. D., & Krumholz, H. M. (2013). When choosing statin therapy: The case for generics. JAMA Internal Medicine, 173(3), 229-232. https://doi.org/10.1001/jamainternmed.2013.1529

When choosing statin therapy : The case for generics. / Green, Jonas B.; Ross, Joseph S.; Jackevicius, Cynthia A.; Shah, Nilay D; Krumholz, Harlan M.

In: JAMA Internal Medicine, Vol. 173, No. 3, 11.01.2013, p. 229-232.

Research output: Contribution to journalArticle

Green, JB, Ross, JS, Jackevicius, CA, Shah, ND & Krumholz, HM 2013, 'When choosing statin therapy: The case for generics', JAMA Internal Medicine, vol. 173, no. 3, pp. 229-232. https://doi.org/10.1001/jamainternmed.2013.1529
Green, Jonas B. ; Ross, Joseph S. ; Jackevicius, Cynthia A. ; Shah, Nilay D ; Krumholz, Harlan M. / When choosing statin therapy : The case for generics. In: JAMA Internal Medicine. 2013 ; Vol. 173, No. 3. pp. 229-232.
@article{585ed14090864d8ebeb4b5ee76aae6b5,
title = "When choosing statin therapy: The case for generics",
abstract = "The development of 'Top 5' lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.",
author = "Green, {Jonas B.} and Ross, {Joseph S.} and Jackevicius, {Cynthia A.} and Shah, {Nilay D} and Krumholz, {Harlan M.}",
year = "2013",
month = "1",
day = "11",
doi = "10.1001/jamainternmed.2013.1529",
language = "English (US)",
volume = "173",
pages = "229--232",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - When choosing statin therapy

T2 - The case for generics

AU - Green, Jonas B.

AU - Ross, Joseph S.

AU - Jackevicius, Cynthia A.

AU - Shah, Nilay D

AU - Krumholz, Harlan M.

PY - 2013/1/11

Y1 - 2013/1/11

N2 - The development of 'Top 5' lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

AB - The development of 'Top 5' lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

UR - http://www.scopus.com/inward/record.url?scp=84874072096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874072096&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2013.1529

DO - 10.1001/jamainternmed.2013.1529

M3 - Article

C2 - 23303273

AN - SCOPUS:84874072096

VL - 173

SP - 229

EP - 232

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -